Clinical trial • Phase I • Infectious Disease

HIV SOSIP v8.2 763 for HIV infection

Phase I trial of HIV SOSIP v8.2 763 for HIV infection. 12 participants.

Overview

Trial Therapeutic Area
Infectious Disease
Trial Disease
HIV infection
Trial Stage
Phase I
Drug Modality
Vaccine

Key dates

Initial CTIS Submission Date
09-01-2025
First CTIS Authorization Date
16-01-2025

Trial design

Phase I trial across 1 site in Spain.

Target Sample Size
12
Trial Duration For Participant
854

Recruitment

Planned Sample Size
12
Recruitment Window Months
28

Geography

Total Number Of Sites
1
Total Number Of Participants
12

Spain

Earliest CTIS Part Ii Submission Date
08-01-2025
Latest Decision Or Authorization Date
16-01-2025
Processing Time Days
8
Number Of Sites
1
Number Of Participants
12

Sites

Site Name
Hospital Clinic De Barcelona
Department Name
HIV Unit
Principal Investigator Name
Josep Mallolas
Principal Investigator Email
mallolas@clinic.cat
Contact Person Name
Josep Mallolas
Contact Person Email
mallolas@clinic.cat
Number Of Participants
12

Sponsor

Primary sponsor

Full Name
Consorcio Centro De Investigacion Biomedica En Red
Organisation Type
Laboratory/Research/Testing facility
Country Of Registered Address
Spain

Investigational products

Investigational Product Name
HIV SOSIP v8.2 763 Vaccine
Active Substance
HIV SOSIP v8.2 763
Modality
Vaccine

Related trials

Other published trials that may interest you.